• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Eargo Inc. (Amendment)

    12/16/22 4:06:18 PM ET
    $EAR
    Medical Specialities
    Health Care
    Get the next $EAR alert in real time by email
    SC 13D/A 1 d382237dsc13da.htm SC 13D/A SC 13D/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    SCHEDULE 13D/A

    (Rule 13d-101)

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 1)*

     

     

    Eargo, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    270087109

    (CUSIP Number)

    Ben Yip

    Nan Fung Trinity (HK) Limited

    Room 1701-1707 Nan Fung Tower

    88 Connaught Road C & 173 Des Voeux Road

    Central, Hong Kong

    Tel. +852 3106 7898

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    December 6, 2022

    (Date of Event Which Requires Filing of This Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.  ☐

     

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 270087109

     

     

      1.    

      NAME OF REPORTING PERSON

      S.S. OR I.R.S. IDENTIFICATION NO. OF REPORTING PERSON (VOLUNTARY)

     

      Nan Fung Group Holdings Limited

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      (a)  ☐        (b)  ☐

      3.  

      SEC USE ONLY

     

      4.  

      SOURCE OF FUNDS

     

      AF

      5.  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

      ☐

      6.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      British Virgin Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7.    

      SOLE VOTING POWER

     

      0

         8.  

      SHARED VOTING POWER

     

      2,958,099*

         9.  

      SOLE DISPOSITIVE POWER

     

      0

       10.  

      SHARED DISPOSITIVE POWER

     

      2,958,099*

    11.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,958,099*

    12.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      0.7%**

    14.  

      TYPE OF REPORTING PERSON

     

      CO

     

    *

    Consists of 293,597 shares of Common Stock directly held by Permwell Management Limited and 2,664,502 shares of Common Stock directly held by Pivotal Alpha Limited. See Item 2(a) of this Schedule 13D/A.

    **

    Based on 39,411,069 shares of Common Stock issued and outstanding as reported on the Issuer’s Form 10-Q filed on November 7, 2022, and an additional 375,000,000 shares of common stock issued and outstanding as reported in Exhibit 99.1 to the Issuer’s Form 8-K filled on December 12, 2022, for a total of 414,411,069 shares of Common Stock issued and outstanding.


    CUSIP No. 270087109

     

     

      1.    

      NAME OF REPORTING PERSON

      S.S. OR I.R.S. IDENTIFICATION NO. OF REPORTING PERSON (VOLUNTARY)

     

      NF Investment Holdings Limited

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      (a)  ☐        (b)  ☐

      3.  

      SEC USE ONLY

     

      4.  

      SOURCE OF FUNDS

     

      AF

      5.  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

      ☐

      6.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      British Virgin Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7.    

      SOLE VOTING POWER

     

      0

         8.  

      SHARED VOTING POWER

     

      2,958,099*

         9.  

      SOLE DISPOSITIVE POWER

     

      0

       10.  

      SHARED DISPOSITIVE POWER

     

      2,958,099*

    11.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,958,099*

    12.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      0.7%**

    14.  

      TYPE OF REPORTING PERSON

     

      CO

     

    *

    Consists of 293,597 shares of Common Stock directly held by Permwell Management Limited and 2,664,502 shares of Common Stock directly held by Pivotal Alpha Limited. See Item 2(a) of this Schedule 13D/A.

    **

    Based on 39,411,069 shares of Common Stock issued and outstanding as reported on the Issuer’s Form 10-Q filed on November 7, 2022, and an additional 375,000,000 shares of common stock issued and outstanding as reported in Exhibit 99.1 to the Issuer’s Form 8-K filled on December 12, 2022, for a total of 414,411,069 shares of Common Stock issued and outstanding.


    CUSIP No. 270087109

     

      1.    

      NAME OF REPORTING PERSON

      S.S. OR I.R.S. IDENTIFICATION NO. OF REPORTING PERSON (VOLUNTARY)

     

      Permwell Management Limited

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      (a)  ☐        (b)  ☐

      3.  

      SEC USE ONLY

     

      4.  

      SOURCE OF FUNDS

     

      WC

      5.  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

      ☐

      6.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7.    

      SOLE VOTING POWER

     

      0

         8.  

      SHARED VOTING POWER

     

      293,597

         9.  

      SOLE DISPOSITIVE POWER

     

      0

       10.  

      SHARED DISPOSITIVE POWER

     

      293,597

    11.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      293,597

    12.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      0.07%*

    14.  

      TYPE OF REPORTING PERSON

     

      CO

     

    *

    Based on 39,411,069 shares of Common Stock issued and outstanding as reported on the Issuer’s Form 10-Q filed on November 7, 2022, and an additional 375,000,000 shares of common stock issued and outstanding as reported in Exhibit 99.1 to the Issuer’s Form 8-K filled on December 12, 2022, for a total of 414,411,069 shares of Common Stock issued and outstanding.


    CUSIP No. 270087109

     

      1.    

      NAME OF REPORTING PERSON

      S.S. OR I.R.S. IDENTIFICATION NO. OF REPORTING PERSON (VOLUNTARY)

     

      Grand Epoch Holdings Limited

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      (a)  ☐        (b)  ☐

      3.  

      SEC USE ONLY

     

      4.  

      SOURCE OF FUNDS

     

      AF

      5.  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

      ☐

      6.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      British Virgin Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7.    

      SOLE VOTING POWER

     

      0

         8.  

      SHARED VOTING POWER

     

      2,664,502*

         9.  

      SOLE DISPOSITIVE POWER

     

      0

       10.  

      SHARED DISPOSITIVE POWER

     

      2,664,502*

    11.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,664,502*

    12.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      0.6%**

    14.  

      TYPE OF REPORTING PERSON

     

      CO

     

    *

    Shares directly held by Pivotal Alpha Limited. See Item 2(a) of this Schedule 13D/A.

    **

    Based on 39,411,069 shares of Common Stock issued and outstanding as reported on the Issuer’s Form 10-Q filed on November 7, 2022, and an additional 375,000,000 shares of common stock issued and outstanding as reported in Exhibit 99.1 to the Issuer’s Form 8-K filled on December 12, 2022, for a total of 414,411,069 shares of Common Stock issued and outstanding.


    CUSIP No. 270087109

     

      1.    

      NAME OF REPORTING PERSON

      S.S. OR I.R.S. IDENTIFICATION NO. OF REPORTING PERSON (VOLUNTARY)

     

      Eternal Sky Holdings Limited

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      (a)  ☐        (b)  ☐

      3.  

      SEC USE ONLY

     

      4.  

      SOURCE OF FUNDS

     

      AF

      5.  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

      ☐

      6.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      British Virgin Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7.    

      SOLE VOTING POWER

     

      0

         8.  

      SHARED VOTING POWER

     

      2,664,502*

         9.  

      SOLE DISPOSITIVE POWER

     

      0

       10.  

      SHARED DISPOSITIVE POWER

     

      2,664,502*

    11.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,664,502*

    12.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      0.6%**

    14.  

      TYPE OF REPORTING PERSON

     

      CO

     

    *

    Shares directly held by Pivotal Alpha Limited. See Item 2(a) of this Schedule 13D/A.

    **

    Based on 39,411,069 shares of Common Stock issued and outstanding as reported on the Issuer’s Form 10-Q filed on November 7, 2022, and an additional 375,000,000 shares of common stock issued and outstanding as reported in Exhibit 99.1 to the Issuer’s Form 8-K filled on December 12, 2022, for a total of 414,411,069 shares of Common Stock issued and outstanding.


    CUSIP No. 270087109

     

      1.    

      NAME OF REPORTING PERSON

      S.S. OR I.R.S. IDENTIFICATION NO. OF REPORTING PERSON (VOLUNTARY)

     

      Pivotal Alpha Limited

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      (a)  ☐        (b)  ☐

      3.  

      SEC USE ONLY

     

      4.  

      SOURCE OF FUNDS

     

      WC

      5.  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

      ☐

      6.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      British Virgin Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7.    

      SOLE VOTING POWER

     

      0

         8.  

      SHARED VOTING POWER

     

      2,664,502

         9.  

      SOLE DISPOSITIVE POWER

     

      0

       10.  

      SHARED DISPOSITIVE POWER

     

      2,664,502

    11.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,664,502

    12.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      0.6%*

    14.  

      TYPE OF REPORTING PERSON

     

      CO

     

    *

    Based on 39,411,069 shares of Common Stock issued and outstanding as reported on the Issuer’s Form 10-Q filed on November 7, 2022, and an additional 375,000,000 shares of common stock issued and outstanding as reported in Exhibit 99.1 to the Issuer’s Form 8-K filled on December 12, 2022, for a total of 414,411,069 shares of Common Stock issued and outstanding.


    CUSIP No. 270087109

     

    SCHEDULE 13D

     

    Item 1.

    Security and Issuer.

    Reference is made to the statement on Schedule 13D filed on October 29, 2020 (the “Original Schedule 13D”) and relates to the Common Stock, $0.0001 par value per share (the “Common Stock”), of Eargo, Inc., a Delaware corporation (the “Issuer”). The address of the principal executive office of the Issuer is 1600 Technology Drive, 6th floor, San Jose, CA 95110.

    This Amendment No. 1 (the “Amendment”) hereby amends and supplements the Original Schedule 13D as described herein. Except as otherwise described herein, the information contained in the Original Schedule 13D remains in effect. Capitalized terms used but not defined in this Amendment shall have the respective meanings set forth thereto in the Original Schedule 13D.

     

    Item 2.

    Identity and Background.

    Item 2 is amended and supplemented as follows:

    (a) The securities of the Issuer reported herein are directly held by Pivotal Alpha and Permwell. Pivotal Alpha is wholly-owned by Eternal Sky, which is wholly-owned by Grand Epoch. Grand Epoch and Permwell are both wholly-owned by NFIHL, which is wholly-owned by NFGHL. The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal Alpha and Permwell. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung,Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Pivotal Alpha, Eternal Sky and Grand Epoch each disclaims beneficial ownership of the securities reported herein as beneficially owned by Permwell and Permwell disclaims beneficial ownership of the securities reported herein as beneficially owned by Pivotal Alpha, Eternal Sky and Grand Epoch.

     

    Item 3.

    Source and Amount of Funds or Other Consideration.

    No changes.

     

    Item 4.

    Purpose of Transaction.

    Item 4 is amended and supplemented as follows:

    Peter Bisgaard, who is a Managing Director of Nan Fung Life Sciences and a Managing Partner of Pivotal Bioventure Partners LLC (both affiliates of the Reporting Persons) resigned his position on the board of directors of the Issuer as of August 3, 2022.

     

    Item 5.

    Interest in Securities of the Issuer.

    Item 5 is amended and supplemented as follows:

    (a)-(b) In addition, Peter Bisgaard directly beneficially owns (i) 41,970 shares of Common Stock, and (ii) a fully vested option to purchase 6,666 shares of Common Stock at an exercise price of $18.00 per share. Mr. Bisgaard resigned his position on the board of directors of the Issuer as of August 3, 2022. Mr. Bisgaard disclaims beneficial ownership of all securities reported as beneficially owned by the Reporting Persons, except to the extent of his pecuniary interest, if any, therein.

    (e) On November 23, 2022, the Issuer issued a total of 375,000,000 shares of Common Stock in connection with a rights offering (the “Rights Offering”) and notes conversion. The Reporting Persons did not participate in the Rights Offering. As a result of the increase to the number of outstanding shares of Common Stock resulting from the Rights Offering, each of the Reporting Persons ceased to be the beneficial owner of more than five percent of the Shares.


    CUSIP No. 270087109

     

    Item 6.

    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    No changes.

     

    Item 7.

    Material to be Filed as Exhibits.

    No changes.


    CUSIP No. 270087109

     

    SIGNATURES

    After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    Dated: December 16, 2022

     

    NAN FUNG GROUP HOLDINGS LIMITED
    By:   /s/ Tang Chun Wai Nelson
    Name:   Tang Chun Wai Nelson
    Title:   Director
    NF INVESTMENT HOLDINGS LIMITED
    By:   /s/ Tang Chun Wai Nelson
    Name:   Tang Chun Wai Nelson
    Title:   Director
    PERMWELL MANAGEMENT LIMITED
    By:   /s/ Tang Chun Wai Nelson
    Name:   Tang Chun Wai Nelson
    Title:   Director
    GRAND EPOCH HOLDINGS LIMITED
    By:   /s/ Tang Chun Wai Nelson
    Name:   Tang Chun Wai Nelson
    Title:   Director
    ETERNAL SKY HOLDINGS LIMITED
    By:   /s/ Tang Chun Wai Nelson
    Name:   Tang Chun Wai Nelson
    Title:   Director
    PIVOTAL ALPHA LIMITED
    By:   /s/ Tang Chun Wai Nelson
    Name:   Tang Chun Wai Nelson
    Title:   Director


    CUSIP No. 270087109

     

    Exhibit A

    AGREEMENT REGARDING THE JOINT FILING OF

    SCHEDULE 13D

     

     

    The undersigned hereby agree that the statement on Schedule 13D, and any amendments thereto, to which this Agreement is annexed as Exhibit A is and will be filed on behalf of each of them in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

    Dated: December 16, 2022

     

    NAN FUNG GROUP HOLDINGS LIMITED
    By:   /s/ Tang Chun Wai Nelson
    Name:   Tang Chun Wai Nelson
    Title:   Director
    NF INVESTMENT HOLDINGS LIMITED
    By:   /s/ Tang Chun Wai Nelson
    Name:   Tang Chun Wai Nelson
    Title:   Director
    PERMWELL MANAGEMENT LIMITED
    By:   /s/ Tang Chun Wai Nelson
    Name:   Tang Chun Wai Nelson
    Title:   Director
    GRAND EPOCH HOLDINGS LIMITED
    By:   /s/ Tang Chun Wai Nelson
    Name:   Tang Chun Wai Nelson
    Title:   Director
    ETERNAL SKY HOLDINGS LIMITED
    By:   /s/ Tang Chun Wai Nelson
    Name:   Tang Chun Wai Nelson
    Title:   Director
    PIVOTAL ALPHA LIMITED
    By:   /s/ Tang Chun Wai Nelson
    Name:   Tang Chun Wai Nelson
    Title:   Director
    Get the next $EAR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EAR

    DatePrice TargetRatingAnalyst
    9/23/2021Outperform → Mkt Perform
    William Blair
    9/23/2021$11.00Overweight → Underweight
    JP Morgan
    9/23/2021$10.00Overweight → Equal-Weight
    Wells Fargo
    More analyst ratings

    $EAR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Eargo downgraded by William Blair

      William Blair downgraded Eargo from Outperform to Mkt Perform

      9/23/21 7:17:15 AM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo downgraded by JP Morgan with a new price target

      JP Morgan downgraded Eargo from Overweight to Underweight and set a new price target of $11.00

      9/23/21 5:05:21 AM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Eargo from Overweight to Equal-Weight and set a new price target of $10.00

      9/23/21 5:03:59 AM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Eargo Debuts Two New Devices, Expanding Portfolio of Hearing Wellness Offerings

      SAN JOSE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- This quarter, Eargo, Inc. launches two new over-the-counter (OTC) hearing wellness devices, Eargo SE (launching today) and LINK by Eargo (launching in the first quarter of 2024). The new devices expand the brand's portfolio of offerings with a new earbud form factor and a completely-in-canal option focused on Eargo signature essentials. For over a decade, Eargo has set the industry standard for pairing award-winning discreet and effortless hearing devices with ongoing expert support. These newest devices address additional consumer needs around functionality, design and experience. Key highlights of each product include: Eargo SE (MSRP$1

      1/31/24 8:00:00 AM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo Celebrates 1-Year Anniversary of FDA's Over-the-Counter (OTC) Hearing Aid Regulations, Driving a New Era of Accessibility and Innovation

      SAN JOSE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo") celebrates the one-year anniversary of the creation of an over-the-counter (OTC) hearing aid category in the US. This important advancement by the US Food & Drug Administration (FDA), following a bipartisan mandate from Congress, was meant to reduce costs, increase competition, improve access, and drive innovation in the hearing aid category, resulting in more widespread adoption of hearing technology. This firmly aligns with Eargo's founding mission. The FDA has noted that the use of hearing aids has been associated with health benefits, improved social participation, and a better quality of life. Th

      11/1/23 8:00:00 AM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo Expands Relationship with Best Buy, Growing In-Store Presence to Over 500 Locations

      SAN JOSE, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced an expansion of its relationship with Best Buy. Eargo devices are now on display in more than 500 Best Buy stores, marking another step in Eargo's retail journey. Approximately 250 of these Best Buy locations will carry Eargo 5–an over-the-counter, FDA-cleared and self-fitting hearing aid–allowing customers to see Eargo's virtually invisible design and purchase in store. Additionally, customers can explore Eargo's full assortment of hearing aids on BestBuy.com. Through this expansion, Eargo continues

      10/26/23 4:01:00 PM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Brownie William returned 296 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Eargo, Inc. (0001719395) (Issuer)

      2/20/24 6:03:54 PM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Narula Onkarr

      4 - Eargo, Inc. (0001719395) (Issuer)

      2/20/24 6:01:45 PM ET
      $EAR
      Medical Specialities
      Health Care
    • Wu David James returned 25,463 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Eargo, Inc. (0001719395) (Issuer)

      2/20/24 5:59:27 PM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    Leadership Updates

    Live Leadership Updates

    See more
    • Eargo Announces Strategic Additions to Board of Directors Following Patient Square Capital Becoming New Majority Shareholder

      SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t

      12/7/22 4:05:00 PM ET
      $EAR
      $ITGR
      $VAPO
      Medical Specialities
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments
    • Eargo Appoints Katie Bayne to Board of Directors

      SAN JOSE, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced the appointment of Katie Bayne to its Board of Directors, effective June 9, 2021. Ms. Bayne will serve as a member of the Nominating and Corporate Governance Committee. The appointment of Ms. Bayne fills the seat vacated by Juliet Tammenoms Bakker, following her resignation from the Board on June 9, 2021. Christian Gormsen, President and CEO, said, “We are incredibly fortunate to welcome Katie to the Eargo team. She is exceptionally qualified and brings decades of experience building one of the mos

      6/10/21 4:30:00 PM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    Financials

    Live finance-specific insights

    See more
    • Eargo Reports Second Quarter 2023 Financial Results

      Recent Highlights: Net revenues of $8.1 million in the second quarter of 2023, up 12% year-over-yearGross systems shipped of 5,098, up 14% year-over-yearGAAP total operating loss $25.8 million in the second quarter of 2023, compared to $31.4 million in the second quarter of 2022In connection with the implementation of the announced cost reduction plan, the Company expects to extend net operating cash runway into the second half of 2024 SAN JOSE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo" or the "Company"), a medical device company on a mission to improve hearing health, today reported its financial results for the second quarter ended June 30, 2023. Will

      8/10/23 4:05:00 PM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo Reports First Quarter 2023 Financial Results

      Recent Highlights: Net revenues of $11.8 million in the first quarter of 2023, up 29% year-over-yearGross systems shipped of 8,705, up 51% year-over-yearGAAP total operating loss $22.8 million in the first quarter of 2023, compared to $30.4 million in the first quarter of 2022Commercially launched Eargo 7, a self-fitting hearing aid with the use of Sound Match via our mobile app, in February 2023Company expects modest sequential improvements to net operating cash burn in the remaining quarters of 2023 SAN JOSE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo" or the "Company"), a medical device company on a mission to improve hearing health, today reported

      5/11/23 4:01:00 PM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo to Report First Quarter 2023 Financial Results on May 11, 2023

      SAN JOSE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR), a medical device company on a mission to improve hearing health, today announced it will release financial results for the first quarter 2023 after market close on May 11, 2023. On the same day, Eargo will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers, using conference ID: 2789592. The live webinar of the call may also be accessed by visiting the Events and Presentations s

      5/4/23 8:00:00 AM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Eargo Inc. (Amendment)

      SC 13D/A - Eargo, Inc. (0001719395) (Subject)

      2/16/24 11:30:56 AM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Eargo Inc. (Amendment)

      SC 13D/A - Eargo, Inc. (0001719395) (Subject)

      10/30/23 5:21:26 PM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Eargo Inc. (Amendment)

      SC 13G/A - Eargo, Inc. (0001719395) (Subject)

      1/6/23 11:49:44 AM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    SEC Filings

    See more
    • SEC Form 15-12G filed by Eargo Inc.

      15-12G - Eargo, Inc. (0001719395) (Filer)

      2/26/24 1:39:45 PM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form S-8 POS filed by Eargo Inc.

      S-8 POS - Eargo, Inc. (0001719395) (Filer)

      2/21/24 12:44:18 PM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form S-8 POS filed by Eargo Inc.

      S-8 POS - Eargo, Inc. (0001719395) (Filer)

      2/21/24 12:44:16 PM ET
      $EAR
      Medical Specialities
      Health Care